Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04626024 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

Study acronym: TOKIN
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 100 to confirmed 17 · Site details revised at 4 of 4 sitesv8 Show 2 more changesShow less
    • Enrollment target: estimated 100 to confirmed 17
    • Site details revised at 4 of 4 sites
  2. Primary and study completion dates: Nov 15, 2025 to Nov 15, 2028v7
  3. Re-verified, no change to tracked fieldsv6
  4. Primary and study completion dates: Nov 15, 2023 to Nov 15, 2025v5
  5. Primary completion date: Nov 15, 2022 to Nov 15, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Eligibility criteria revisedv3 See this version in full on ClinicalTrials.gov ↗
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 15, 2020 to Dec 22, 2020 · Site details revised at 4 of 4 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Nov 15, 2020 to Dec 22, 2020
    • Site details revised at 4 of 4 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Trial Details
NCT Number NCT04626024
Lead Sponsor Baylor College of Medicine
Conditions Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov